Conference Coverage

Drug coated balloons may match stents for small coronary lesions



WASHINGTON – For treating de novo coronary lesions in vessels smaller than 2.75 mm, drug coated balloon angioplasty is as safe and may be as effective as drug-eluting stents, according to a multicenter randomized trial presented as a late-breaker at CRT 2018 sponsored by the Cardiovascular Research Institute at Washington Hospital Center.

Ted Bosworth/Frontline Medical News

Dr. Victor A. Jimenez Dias

De novo lesions in small coronary vessels are a clinical challenge, according to Dr. Jimenez Diaz. These are associated with relatively high rates of restenosis. They are also associated with a vessel thrombosis rate of 1% within 6 months, and a small but significant risk of major adverse cardiac events, variably estimated to range between 6% and 10% at 1 year. There is no uniformly accepted standard for treatment.

In this study, 94 patients with de novo coronary lesions in small diameter vessels were randomized to treatment with a paclitaxel drug coated balloon (DCB) (IN.PACT Falcon, Medtronic) or a zotarolimus drug-eluting stent (DES) (Resolute Integrity, Medtronic). Lesions in vessels between 2.0 and 2.75 mm in diameter were eligible; 137 lesions were treated in a study with seven participating centers in Spain.


Recommended Reading

OSA may provide cardioprotection
MDedge Cardiology
VIDEO: Patient vouchers prompt physicians to prescribe top antiplatelet drugs
MDedge Cardiology
Radial access PCI best for acute coronary syndrome patients
MDedge Cardiology
Febuxostat increases cardiovascular mortality in CARES trial
MDedge Cardiology
DOACs may be beneficial in post-op atrial fib after CABG
MDedge Cardiology